Posted by Michael Wonder on 20 Jan 2018
The FDA should shine more light on drug rejections
19 January 2018 - The status quo helps companies doll up failures, hurting investors and public health.
C,R, and L are the three most dreaded letters in biotech -- shorthand for complete response letters, which the FDA sends when it rejects a drug application. They can delay or derail a drug's path to market.
The FDA sends these letters privately, and companies often obfuscate or spin their contents to the detriment of investors and the public.
